<DOC>
	<DOCNO>NCT00484003</DOCNO>
	<brief_summary>The study evaluate safety effect pimecrolimus cream 1 % quality life caregiver South African child mild moderate atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>A Quality Life Safety Study With Pimecrolimus Cream , 1 % Children ( Age 2-12 Years ) With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Male female Age ≥2 year ≤12 year age Atopic dermatitis sensitive skin area ( i.e . face , neck flexure ) Subjects treatment modality inadvisable accord investigator 's clinical opinion fail treatment modality due intolerance inadequate response . Patients history mild moderate AD Subjects present visit 1 clear clinical diagnosis mild moderate AD . Subject 's parent legal guardian must inform study procedure must sign Informed Consent form approve study prior study related procedure Subjects active viral infection site ( ) treatment . In presence dermatological infection , use appropriate antimicrobial agent institute . Subjects present systemic malignancy active lymphoproliferative diseases/disorders ( e.g. , lymphoma , neoplastic disease , chronic lymphoproliferation ) . Subjects present clinical condition AD , opinion investigator , interfere evaluation Subjects receive phototherapy ( e.g. , PUVA , UVB ) immunosuppressive therapy ( e.g. , cyclosporine , FK506 [ tacrolimus ] ) . Subjects use investigational drug within 8 week prior first application study medication intend use investigational drug course study . Subjects use , use 0.03 % 0.1 % tacrolimus ointment . Pimecrolimus cream 1 % contraindicated subject know suspected hypersensitivity pimecrolimus component cream Subjects medically stable subject condition , opinion investigator , render subject ineligible study . Pregnancy lactation ( applicable ) Pimecrolimus cream 1 % use pregnancy lactation Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Atopic eczema</keyword>
	<keyword>Pimecrolimus</keyword>
	<keyword>Children</keyword>
	<keyword>Quality life</keyword>
	<keyword>Safety</keyword>
	<keyword>Atopic dermatitis</keyword>
</DOC>